title: Advantages of a unique DNA-based vaccine in comparison to paclitaxel in treatment of an established intracerebral breast cancer in mice.
abstract: In this study we compared the benefits of treating C3H/He mice with an established intracerebral breast carcinoma by immunization with a unique DNA-based vaccine to chemotherapy with paclitaxel. Prior studies revealed the immunotherapeutic properties of a vaccine prepared by transfer of genomic DNA from breast cancer cells into a highly immunogenic cell line. Here, C3H/He mice with an established intracerebral breast cancer were treated either by injection into the tumor bed through a unique cannula system with the cell based vaccine or with paclitaxel administered intraperitoneally. Both treatment strategies were effective in prolonging survival and stimulating a systemic anti-tumor immune response (p< 0.025). However, unlike mice treated with the vaccine, the animals that received paclitaxel alone displayed significant toxic side effects. No additional therapeutic advantage was detected when these two treatment strategies were combined. The vaccine tended to provide a somewhat better therapeutic and clearly better systemic immunologic effect based on two independent spleen cell assays in comparison to paclitaxel.
authors.forename: Terry
authors.initials: T
authors.lastname: Lichtor
authors.forename: Roberta P
authors.initials: RP
authors.lastname: Glick
authors.forename: Henry
authors.initials: H
authors.lastname: Lin
authors.forename: Amla
authors.initials: A
authors.lastname: Chopra
authors.forename: Insug
authors.initials: I
authors.lastname: O-Sullivan
authors.forename: Edward P
authors.initials: EP
authors.lastname: Cohen